Transcranial photobiomodulation improves sleep quality, reduces daytime sleepiness, and modulates delta power in chronic insomnia.
Transcranial photobiomodulation improves sleep quality, reduces daytime sleepiness, and modulates delta power in chronic insomnia: a randomized controlled trial.
AI Summary
Key Findings
Abstract
Chronic insomnia is a prevalent disorder with significant health consequences and limitations in current treatments. This randomized controlled trial evaluated the efficacy of transcranial photobiomodulation (tPBM) on subjective sleep quality, daytime sleepiness, and quantitative EEG biomarkers in chronic insomnia. Thirty adults with chronic insomnia (DSM-5 criteria) were randomized to receive active tPBM (n = 15) or sham treatment (n = 15). Active tPBM (810 nm wavelength; 250mW/cm²irradiance; 60 J/cm²energy density) was applied to frontal cortical regions for 10 min per session over 3 consecutive days. Primary outcomes were Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and absolute delta power (1-4 Hz) at frontal EEG sites, assessed at baseline and 1-week post-treatment. Significant improvements were observed in the tPBM group compared to sham: PSQI global score (mean difference: -4.6 points; 95% CI: -7.2 to -2.0; p = 0.004,η²=0.272), ESS total score (mean difference: -4.1 points; 95% CI: -6.8 to -1.4; p = 0.015,η²=0.209), and absolute delta power at multiple frontal sites (e.g., Fp1: p = 0.001,η²=0.418; Fz: p
Affiliation
Masoud Mehdizadeh
External References
- PubMed ID:
- 41125953
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.